Xeloda Or 5-FU Combined With Oxaliplatin Therapy For Metastatic Colorectal Cancer:a Meta-analysis

Objective To compare clinical outcomes and safety of 5-FU or xeloda combined withoxaliplatin therapy for Metastatic colorectal cancerMethods Literature search were performed by key words, such as Metastatic colorectalcancer, xeloda, oxaliplatin, 5-FU on all randomized controlled trails reported on 5-FU or xelodacombined with oxaliplatin therapy for Metastatic colorectal cancer before JUN. 2011. Twoauthors drew the details of trail design, characteristics of patients, outcomes and so on from thestudies included. Date analysis was performed by RevMan 4.2.Results According to the same screening criteria, 6 clinical studies were included in thismeta-analysis. Sample volume in this meta-analysis was 2189 colorectal cancer cases. Thebaseline characteristics of 5-FU group were similar to those of xeloda group. The short-termoutcome such as response rate, Complete response ,partial response, Duration ofstabilization ,Disease progression. and the long-term outcome such as median overall survival,median Time to progression, Median duration of response, median progression-free survival, twogroup were similar. In the comparison of III～IV grade toxicity between the two groups, theincidences of Neutropenic in 5-FU group were higher than those in xeloda group, and the RRwas 0.24[95%CI(0.11,0.55), p=0.0007]，respectively. However, the incidence of Hand-footsymptoms in 5-FU group was lower than those in xeloda group, the RR was2.83[95%CI(1.66,4.82), p=0.0001], respectively.Conclusions Both 5-FU and xeloda were similler effective in the therapy of Metastaticcolorectal cancer. And the III～IV grade toxicity such as Neutropenic was easier to happen in5-FU group, while the incidence of Hand-foot symptoms was on the other hand.